DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hydromet (Hydrocodone Bitartrate / Homatropine Methylbromide) - Summary

 
 



HYDROMET SUMMARY

This product contains hydrocodone (dihydrocodeinone) bitartrate, a semisynthetic centrally acting narcotic antitussive. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage.

HYDROMET (HYDROCODONE/METHYLHOMATROPINE) is indicated for the following:

For the symptomatic relief of cough.


See all Hydromet indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Hydromet (Hydrocodone / Homatropine)

Medical News Today: Flu risk: cover your cough at Superbowl celebrations
Source: Featured Health News from Medical News Today [2016.02.06]
Superbowl parties and gatherings can spread influenza, putting the lives of over-65s at risk. Researchers advise party-goers to take extra precautions while celebrating.

Flu risk: cover your cough at Superbowl celebrations
Source: Flu / Cold / SARS News From Medical News Today [2016.02.06]
Superbowl parties and gatherings can spread influenza, putting the lives of over-65s at risk. Researchers advise party-goers to take extra precautions while celebrating.

Waning Whooping Cough Immunity Blamed in Outbreaks
Source: MedicineNet Chronic Cough Specialty [2016.02.05]
Title: Waning Whooping Cough Immunity Blamed in Outbreaks
Category: Health News
Created: 2/5/2016 12:00:00 AM
Last Editorial Review: 2/5/2016 12:00:00 AM

Whooping cough booster vouchers don't boost immunization rates of caregivers
Source: Caregivers / Homecare News From Medical News Today [2016.02.04]
Cases of pertussis (whooping cough) have increased dramatically over the past five years, putting infants at risk of serious illness or death.

Try Home Remedies for Child's Cough or Cold
Source: MedicineNet Chronic Cough Specialty [2016.01.06]
Title: Try Home Remedies for Child's Cough or Cold
Category: Health News
Created: 1/5/2016 12:00:00 AM
Last Editorial Review: 1/6/2016 12:00:00 AM

more news >>

Published Studies Related to Hydromet (Hydrocodone / Homatropine)

Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. [2003.01]
RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief. OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers... CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.

more studies >>

Clinical Trials Related to Hydromet (Hydrocodone / Homatropine)

Single Dose Pharmacokinetics of Egalet´┐Ż Hydrocodone [Completed]

Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients [Completed]
Objective is to evaluate the pharmacokinetics profile of hydrocodone's metabolite hydromorphone in patients who are taking hydrocodone on a routine basis for more than 3 months for chronic pain and correlate hydromorphone levels to their hydrocodone usage.

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction [Completed]
The purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen compared to placebo in moderate to severe pain following molar extraction.

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain [Completed]
The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe chronic low back pain uncontrolled by their current stable analgesic regimen

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. [Completed]
The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.

more trials >>


Page last updated: 2016-02-06

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015